局部晚期食管癌剂量递增放疗随机试验的质量保证
PURPOSE: The ongoing phase 2/3 PRODIGE 26/CONCORDE trial compares chemoradiation therapy with and without dose escalation in patients with locally advanced or unresectable esophageal cancer.…
要点
- 基准病例质控显示仅32.6%计划完全符合方案,25.6%被拒绝。
- 心脏剂量约束偏差最常见,约三分之一计划存在偏差。
核心结论
- 方案偏差频率高,凸显临床试验中质量保证程序的重要性。
研究设计与样本
- PRODIGE 26/CONCORDE 2/3期随机试验的质量保证部分,各参与中心对共同基准病例制定治疗计划。
- 评估靶区勾画、靶区覆盖和危及器官剂量约束,计划分为符合方案、可接受轻微偏差(MiD)或不可接受重大偏差(MaD)。
主要发现
- 14份(32.6%)计划符合方案,19份(44.2%)至少1个MiD,2份(4.6%)至少1个MaD,8份(18.6%)同时有MiD和MaD。
- 总体11份(25.6%)计划被拒绝,仅1份因大体肿瘤体积勾画不正确被拒,危及器官勾画所有病例均合规。
- 心脏剂量约束偏差最常见,约三分之一计划存在偏差;靶区方面3份(5.8%)计划存在重大剂量不足,1份(1.9%)存在重大剂量过高。
关键数值与推荐
- 计划拒绝标准:存在≥4个MiD或1个MaD。
- 计划分类:符合方案、MiD、MaD。
临床怎么用
- 参与剂量递增放疗试验的中心应执行基准病例质控以评估方案依从性。
- 调强放疗可能提高计划接受率,但需注意心脏剂量约束。
局限性
- 基准病例质控结果不能直接反映实际患者治疗的计划质量。
- 质量保证对患者结局的影响尚未评估,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The ongoing phase 2/3 PRODIGE 26/CONCORDE trial compares chemoradiation therapy with and without dose escalation in patients with locally advanced or unresectable esophageal cancer. The results of a benchmark case procedure are reported here to evaluate the protocol compliance of participating centers as part of quality assurance for radiation therapy. METHODS AND MATERIALS: Volume delineation, target coverage, and dose constraints to the organs at risk (OARs) were assessed on treatment plans of a common benchmark case performed by each participating center. The centers were classified in 3 categories: per protocol, minor acceptable deviation (MiD), or major unacceptable deviation (MaD). A plan was rejected if ≥4 MiDs or 1 MaD were found. RESULTS: Thirty-5 centers submitted 43 plans. Among them, 14 (32.6%) were per protocol, 19 (44.2%) presented at least 1 MiD, 2 (4.6%) presented at least 1 MaD, and 8 (18.6%) presented both MiD and MaD. Overall, 11 (25.6%) plans were rejected. Only 1 plan was rejected because gross tumor volume was not correctly delineated. The OAR delineation was respected in all cases. Dose constraints to the OARs were respected in the majority of cases except for the heart, where one-third of the plans presented a deviation. As for the target volume, 3 plans (5.8%) had a major underdosage and 1 plan (1.9%) had a major overdosage. Overall, 58% of all treatments were planned with intensity modulated radiation therapy, whereas 42% were planned with 3-dimensional chemoradiation therapy. Significantly more plans in the intensity modulated radiation therapy group were accepted compared with the 3-dimensional chemoradiation therapy group (P = .03). CONCLUSION: The high frequency of protocol deviations underlines the importance of a quality assurance program in clinical trials. Further work should assess the impact of quality assurance for radiation therapy on patient outcomes.
引用
- Boustani J, Rivin Del Campo E, Blanc J, et al. Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31299242. doi:10.1016/j.ijrobp.2019.06.2542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。